glp 1 san diego UC researchers explore whether a GLP-1 drug can slow biological aging Opinion: Women pay the price
Description
Engineering nanoplatforms for theranostics of atherosclerotic plaques
[DOI] [PMC free article] [PubMed] [Google Scholar] 160
Unlike conventional injectable GLP-1 receptor agonists, these orally administered small-molecule therapies offer a more convenient treatment option, improving patient adherence, accessibility, and overall treatment experience
Wegovy is the same molecule at a higher dose (2.4 mg/week) approved specifically for weight management
In-depth details Helpful context, usage notes, and comparisons
